Combimet^? improves glycemic control in patients with type 2 diabetes. Glipizide appears to lower blood glucose acutely by stimulating the release of insulin from the pancreas. Metformin Hydrochloride is an antihyperglycemic agent that improves glucose tolerance in patients with type 2 diabetes,lowering both basal and postprandial plasma glucose.Combimet? is indicated as initial therapy,as an adjucent to diet and excercise, whose hyperglycemia cannot be satisfactorily managed with diet and excersise alone.It is also indicated for second line therapy when diet, excercise and initial treatment with metformin or glipizide alone do not result in adequate glycemic control in patients with type 2 diabetes.

Diactin^? is an oral blood glucose lowering drug of the sulfonylurea class. Diactin^? is used to treat patients with type 2 diabetes mellitus or non-insulin dependent diabetes mellitus (NIDDM). Type 2 diabetes mellitus is a condition in which the body does not make enough insulin or where the insulin that the body produces does not work as well as it should. Insulin is a natural body chemical that helps the body's cells use the sugar from the blood and so stops the blood sugar levels from rising too high. High blood sugar levels can cause damage to the body's cells. Diactin^? lowers the blood glucose by stimulating release of insulin from pancreatic beta cells and by increasing the sensitivity of peripheral tissues to insulin. Diactin^? is indicated as an adjunct to diet for the control of hyperglycaemia and its associated symptomatology in the treatment of non-insulin-dependent diabetes mellitus (NIDDM; type II) when diet modification has not been proved effective on its own. In certain patients who are receiving insulin, the concurrent use of Diactin would allow a reduction in the daily dose of insulin.

Diaglit^? (Pioglitazone) is a member of the newest class of oral antidiabetic agent called thiazolidinediones that depends on the presence of insulin for its mechanism of action. Pdiglitone decreases insulin resistance in the periphery and in the liver, resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. It also improves abnormality in lipid metabolism by activating PPAR. ? (Peroxisome Proliferator Activated Receptor Gamma) receptor. Diaglit^? is indicated as an adjunct to diet and exercise to improve glycaemic control in patients with type II diabetes (NIDDM). Diaglit^? is indicated for monotherapy and also indicated for use in combination with sulfonylurea, metformin or insulin when diet and exercise plus the single agent does not result in adequate glycaemic control.

Diapro^? is an oral blood glucose lowering drug of the sulfonylurea class. Diaryl^? is used to treat patients with type 2 diabetes mellitus or non-insulin dependent diabetes mellitus (NIDDM). The primary mechanism of action of Diaryl^? is lowering of blood glucose by stimulating the release of insulin from functioning pancreatic beta cells. In addition, expancreatic effects may also play vital role in the activity of Diaryl^? i . Administration of Diaryl^? can lead to increase sensitivity of peripheral tissues to insulin.Diaryl^? is indicated for non-insulin dependent (type-II) diabetes, whenever blood sugar levels cannot be controlled adequately by diet, physical exercise and weight reduction. Diaryl^? (Glimepiride) is also indicated for use in combination with insulin to lower blood glucose in patients whose hyperglycaemia can not be controlled by diet and exercise or in conjunction with an oral hypoglycaemic agent.

Diaryl^? is an oral blood glucose lowering drug of the sulfonylurea class.Diaryl^? is used to treat patients with type 2 diabetes mellitus or non-insulin dependent diabetes mellitus (NIDDM). The primary mechanism of action of Diaryl^? is lowering of blood glucose by stimulating the release of insulin from functioning pancreatic beta cells. In addition, expancreatic effects may also play vital role in the activity of Diaryl^? . Administration of Diaryl^? can lead to increase sensitivity of peripheral tissues to insulin. Diaryl^? is indicated for non-insulin dependent (type-II) diabetes, whenever blood sugar levels cannot be controlled adequately by diet, physical exercise and weight reduction.Diaryl^? is also indicated for use in combination with insulin to lower blood glucose in patients whose hyperglycaemia can not be controlled by diet and exercise or in conjunction with an oral hypoglycaemic agent.

Informet^? and Informet^? LA are used to treat type 2 diabetes. This is also known as non-insulin-dependent diabetes mellitus. People with type 2 diabetes are not able to make enough insulin or respond normally to the insulin their bodies make. When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems including kidney damage, amputations, and blindness. Diabetes is also closely linked to heart disease. The main goal of treating diabetes is to lower your blood sugar to a normal level. Informet^? and Informet^? LA have the same active ingredient metformin. However, Informet^? LA works longer in your body. Both of these medicines help control your blood sugar in a number of ways. These include helping your body respond better to the insulin it makes naturally, decreasing the amount of sugar your liver makes, and decreasing the amount of sugar your intestines absorb. Informet^? and Informet^? LA do not cause your body to make more insulin. Because of this, when taken alone, they rarely cause hypoglycemia (low blood sugar), and usually do not cause weight gain. However, when they are taken with a sulfonylurea or with insulin, hypoglycemia is more likely to occur, as is weight gain.

Premil^? is an oral blood glucose lowering drug. The active ingredient of Premil^? is Repaglinide. Repaglinide belongs to a new class of oral antidiabetic drug called meglitinide which stimulates insulin release from ?-cells of pancreas. Repaglinide is indicated as an adjunct to diet and exercise to lower the blood glucose level in patients with type 2 diabetes mellitus (NIDDM) whose hyperglycaemia cannot be controlled satisfactorily by diet and exercise alone. It is also indicated for use in combination with metformin to lower blood glucose in patients whose hyperglycaemia cannot be controlled by exercise, diet, and either Repaglinide or metformin alone. Repaglinide binds to specific receptors in the ?-cell membrane leading to the closure of ATP-dependent K+ channels and the depolarization of ?-cell membrane. This in turn, leads to Ca++ influx, increased intracellular Ca++ and the stimualtion of insulin secretion.